Compounds > oxazoles
Page last updated: 2024-08-21

oxazoles and Breast Cancer

oxazoles has been researched along with Breast Cancer in 77 studies

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-19905 (6.49)18.7374
1990's5 (6.49)18.2507
2000's5 (6.49)29.6817
2010's21 (27.27)24.3611
2020's41 (53.25)2.80

Authors

AuthorsStudies
Ghazanfari, L; Kabanov, AV; Master, A; Seo, Y; Sokolsky-Papkov, M; Vishwasrao, HM; Wan, X1
Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T1
Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB1
Baranovsky, AV; Khamidullina, AI; Khlebnicova, TS; Lakhvich, FA; Piven, YA; Rusanova, JA; Scherbakov, AM; Tatarskiy, VV; Yastrebova, MA; Zinovich, VG1
Borges, V; Cameron, D; Carey, LA; Curigliano, G; Feng, W; Gelmon, K; Hamilton, E; Hortobagyi, GN; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Murthy, R; Okines, A; Paplomata, E; Pegram, M; Ramos, J; Slamon, D; Winer, E1
Bachelot, T; Bailleux, C; Darlix, A; Jacot, W1
Ahn, D; Bekaii-Saab, T; Walden, D1
Feng, Y; Fu, X; Li, Z; Lin, F; Lv, J; Mao, Q; Mou, Y; Wang, S; Yang, Y; Zhang, B; Zhang, L; Zhang, P; Zhao, J1
Ennett, MD; Kaplan, HG; Kullnat, JA; Rinn, KJ; Scott, EL; Wu, AY; Yan, F1
Ayala, R; Gong, KW; Huang, HKT; Issakhanian, S; Lu, M; Luo, T; Madrid, AM; McDermott, MSJ; O'Brien, NA; Slamon, DJ; Zhang, J1
Sahu, RP; Sirhan, Z; Thyagarajan, A1
Gong, Y; Hu, M; Li, J; Li, Y; Liu, C; Liu, Z; Xie, Y; Ying, B; Zhou, H1
DeChenne, S; Foerder, CA; Hengel, SM; Meyer, JA1
Abramson, V; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Braga, S; Cameron, D; Carey, LA; Curigliano, G; Duhoux, FP; Feng, W; Gelmon, K; Greil, R; Hamilton, E; Hortobagyi, G; Hurvitz, SA; Jakobsen, E; Krop, I; Lin, NU; Loi, S; Loibl, S; Müller, V; Murthy, RK; Okines, A; Oliveira, M; Palanca-Wessels, MC; Paplomata, E; Pegram, M; Shachar, SS; Slamon, D; Walker, L; Winer, EP1
Printz, C1
Barry, WT; Freedman, RA; Krop, I; Lawler, E; Leone, JP; Li, T; Lin, NU; Metzger Filho, O; Tan-Wasielewski, Z; Tolaney, SM; Trippa, L; Walker, L; Winer, EP; Younger, J1
Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A1
Benson, JR; Dumitru, D; Jatoi, I1
Lee, A1
Rugo, HS1
Ameratunga, M; Aspegren, J; Bono, P; Braña, I; de Bono, JS; Korjamo, T; Plummer, R; Postel-Vinay, S; Snapir, A1
Gelmon, KA; Tesch, ME1
Amiri-Kordestani, L; Beaver, JA; Chen, W; Chen, XH; Cheng, J; Fan, J; Fiero, MH; Goldberg, KB; Gong, Y; Li, F; Pazdur, R; Pierce, WF; Ricks, TK; Shah, M; Song, P; Tang, S; Theoret, MR; Wedam, S; Xia, H; Yu, J; Zhang, X1
Curigliano, G; Prat, A; Tarantino, P1
Crimini, E; Curigliano, G; Giugliano, F; Morganti, S; Tarantino, P; Uliano, J1
Cardoso, F; Cortes, J; Curigliano, G; Prat, A; Tarantino, P1
Munshi, A; Singla, H1
Exman, P; Tolaney, SM1
Boikos, SA; Dozmorov, MG; E Koblinski, J; Faber, AC; Fairchild, CK; Floros, KV; Hu, B; Jacob, S; Kurupi, R; Puchalapalli, M; Scaltriti, M1
Corti, C; Criscitiello, C1
Kreipe, HH; Sinn, P1
Isaacs, C; O'Regan, R; O'Shaughnessy, JA1
Bolat, ZB; Bozkır, A; Devrim, B; Gulyuz, S; Ozkose, UU; Şahin, F; Telci, D; Yilmaz, O1
Borsellino, N; Galanti, D; Gori, S; Incorvaia, L; Inno, A; La Vecchia, M; Russo, A1
Martínez-Sáez, O; Prat, A1
Bishopric, NH; Dabas, N; Dempsey, N; Kropotova, Y; Lippman, M; Rosenthal, A1
Hua, J; Sun, Y; Yuan, Y; Zhang, L; Zhang, Z1
Aithal, S; Arkenau, HT; Block, M; Boyle, F; Brenner, A; Cameron, D; Cancel, M; Cold, S; Colleoni, M; Crouzet, L; Curigliano, G; Curtit, E; DeBusk, K; Fehrenbacher, L; Feng, W; Ferrario, C; Gelmon, K; Hahn, O; Hamilton, E; Harder Brix, E; Iqbal, N; Jakobsen, E; Mueller, V; Muñoz-Mateu, M; Paplomata, E; Poosarla, T; Ramos, J; Siadak, M; Stringer-Reasor, E; Wardley, A; Zelnak, A1
Dong, L; Li, Y; Lin, S; Nian, D; Wang, R; Weng, X; Xu, X; Zhong, L; Zhou, W1
Dong, X; Jiang, H; Li, H; Liu, Y; Ma, L; Meng, L; Ran, R; Song, G; Sun, Y; Tong, Y; Wang, M; Yan, H; Zhang, J; Zhang, R; Zhou, Q1
Bartolini, S; Brandes, AA; Di Battista, M; Di Nunno, V; Franceschi, E; Gatto, L; Lodi, R; Maggio, I; Minichillo, S; Mura, A; Tosoni, A1
Ehrsam, D; Lengerke, C; Meyer Zu Schwabedissen, HE; Porta, F1
Beaudoin, JJ; Bludau, H; Jordan, R; Kabanov, AV; Makita, N; Min, Y; Sokolsky, M; Vinod, N; Wan, X; Wang, A1
Allingham, JS; Craig, AW; Evans, PA; Nersesian, S; Newsted, D; Shah, K; Williams, R; Young, S1
Endo, Y; Inoue, K; Min, JZ; Mochizuki, T; Todoroki, K; Toyama, T; Toyo'oka, T; Tsutsui, H; Yoshimoto, N1
Cabrita, MA; Durst, T; Lau, R; McGregor, C; McKay, BC; Murphy, LC; Pratt, MA; Ruddy, SC; Wright, JS1
Chen, J; Liao, C; Liu, J; Tang, H; Wu, S; Xie, G1
Bergès, R; Brouland, JP; Canivenc-Lavier, MC; Perrot-Applanat, M; Phrakonkham, P; Pimpie, C; Pocard, M; Saad, Hel S1
Huang, W; Wu, QD; Xu, JH; Ye, M; Zhang, LR; Zhang, M; Zheng, W1
Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W1
Alakhova, DY; Bludau, H; Darr, DB; He, Z; Jordan, R; Kabanov, AV; Luxenhofer, R; Ojima, I; Perou, CM; Schulz, A; Seitz, J; Wan, X1
Atmaca, H; Bozkurt, E; Erdogan, AP; Gursoy, P; Karaca, B; Şanlı, UA; Sezgin, C; Surmeli, Z; Uslu, R; Uzunoglu, S1
Alakhova, D; Bludau, H; Darr, DB; Dobrovolskaia, MA; He, Z; Jordan, R; Kabanov, AV; Li, Z; Luxenhofer, R; Montgomery, SA; Perou, CM; Schulz, A; Sokolsky, M; Stern, ST; Wan, X; Yuan, H1
Akudugu, JM; Hamunyela, RH; Serafin, AM1
Chang, EC; Charn, TH; Katzenellenbogen, BS; Katzenellenbogen, JA; Lee, YK; Liu, ET1
Batrakova, EV; Bronich, TK; Jordan, R; Kabanov, AV; Li, S; Luxenhofer, R; Roques, C; Schulz, A1
LaVoie, EJ; Liu, A; Liu, L; Pilch, DS; Rice, JE; Rzuczek, SG1
Chakraborty, A; Chatterjee, S; Roy, P1
Bacconi, A; Corbu, A; Fowler, VM; Jiang, X; Lindsay-Scott, PJ; Nicolaou, KC; Yamashiro, S1
Chen, C; Harper, MK; Kapadia, A; LaBarbera, DV; Li, Q; Schaack, J; Zhou, Q1
Amatori, S; Ambrosi, G; Barone, G; Fanelli, M; Fusi, V; Giorgi, L; Terenzi, A; Turco Liveri, V1
Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY1
Cress, WD; Freeman, SN; Ma, Y1
Dannals, RF; Foss, CA; Henke, BR; Mathews, WB; Pomper, MG; Ravert, HT; Stoermer, D1
Ide, T; Seimiya, H; Shin-Ya, K; Tahara, H; Tsuruo, T; Yamada, H1
Boon-Unge, K; Govitrapong, P; Yu, Q; Zhou, A; Zhou, J; Zou, T1
Adamson, D; Bryant, PE; Riches, AC; Shovman, O1
Allen, LM; Thornthwaite, JT1
Bodey, G; Fleishman, G; Murphy, WK; Yap, HY1
Bøe, R; Døskeland, SO; Gjertsen, BT; Vintermyr, OK1
Larrick, JW; Torti, FM; Wright, SC; Zheng, H; Zhong, J1
Cunningham, A; Lazo, JS; Rice, RL; Wipf, P1
Chubb, CH; Fujiki, H; Giometti, C; Huberman, E; Kiguchi, K1
Bailey, H; Earhart, RH; McGovren, JP; Williams, MG1
Chang, YC; Falkson, G; Knuiman, MW; Pandya, KJ; Skeel, RT; Willson, JK; Wolter, JM1
Booth, BW; Budman, D; Ellison, RR; Khojasteh, A; Korzun, AH; Weiss, RB; Wood, W1
Beierwaltes, WH; Ryo, UY1

Reviews

13 review(s) available for oxazoles and Breast Cancer

ArticleYear
    Bulletin du cancer, 2021, Volume: 108, Issue:11S

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab

2021
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer.
    Military Medical Research, 2022, 07-13, Volume: 9, Issue:1

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; United States

2022
Tucatinib: First Approval.
    Drugs, 2020, Volume: 80, Issue:10

    Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Humans; Molecular Structure; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2

2020
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Drugs, 2020, Volume: 80, Issue:17

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2020
Margetuximab for the treatment of HER2-positive metastatic breast cancer.
    Expert opinion on biological therapy, 2021, Volume: 21, Issue:2

    Topics: Antibodies, Monoclonal; Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2021
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box.
    Biochimica et biophysica acta. Reviews on cancer, 2021, Volume: 1875, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Oxazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab

2021
HER2-positive metastatic breast cancer: a comprehensive review.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab

2021
[Relevant mutations in predictive breast cancer pathology].
    Der Pathologe, 2021, Volume: 42, Issue:4

    Topics: Breast Neoplasms; Female; Humans; Mutation; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2

2021
Current treatment options for HER2-positive breast cancer patients with brain metastases.
    Critical reviews in oncology/hematology, 2021, Volume: 161

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab

2021
Current and Future Management of HER2-Positive Metastatic Breast Cancer.
    JCO oncology practice, 2021, Volume: 17, Issue:10

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines

2021
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Breast cancer research and treatment, 2021, Volume: 188, Issue:1

    Topics: Breast Neoplasms; Cardiotoxicity; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Risk Factors; Trastuzumab

2021
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?
    Clinical drug investigation, 2021, Volume: 41, Issue:9

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2

2021
Progesterone receptor agonists and antagonists as anticancer agents.
    Mini reviews in medicinal chemistry, 2010, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Estrenes; Estrogens; Female; Humans; Oxazoles; Progesterone; Pyrazoles; Receptors, Progesterone; Uterine Neoplasms

2010

Trials

9 trial(s) available for oxazoles and Breast Cancer

ArticleYear
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    Future oncology (London, England), 2021, Volume: 17, Issue:34

    Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2

2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab

2022
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    The New England journal of medicine, 2020, 02-13, Volume: 382, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Consolidation Chemotherapy; Diarrhea; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Oxazoles; Progression-Free Survival; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 08-10, Volume: 38, Issue:23

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult

2020
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    British journal of cancer, 2020, Volume: 123, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Blood Platelets; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Oxazoles; Prostatic Neoplasms, Castration-Resistant; Proteins; Pyridines; Quinolines; Sarcoma; Small Cell Lung Carcinoma; Young Adult

2020
Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer.
    Breast cancer research and treatment, 2021, Volume: 189, Issue:3

    Topics: Androgen Receptor Antagonists; Animals; Breast Neoplasms; Female; Humans; Mice; Oxazoles; Receptors, Androgen; Thiohydantoins

2021
Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Central Nervous System Diseases; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Isoxazoles; Middle Aged; Neoplasm Metastasis; Oxazoles

1986
Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Brain Diseases; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Hematologic Diseases; Humans; Isoxazoles; Middle Aged; Neoplasm Metastasis; Oxazoles

1986

Other Studies

55 other study(ies) available for oxazoles and Breast Cancer

ArticleYear
Poly(2-oxazoline)-magnetite NanoFerrogels: Magnetic field responsive theranostic platform for cancer drug delivery and imaging.
    Nanomedicine : nanotechnology, biology, and medicine, 2022, Volume: 39

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Ferrosoferric Oxide; Humans; Magnetic Fields; Micelles; Oxazoles; Paclitaxel; Precision Medicine

2022
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
    Nature communications, 2021, 11-18, Volume: 12, Issue:1

    Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape

2021
Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells.
    Bioorganic & medicinal chemistry, 2022, 01-01, Volume: 53

    Topics: Acylation; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Models, Molecular; Molecular Structure; Oxazoles; Oximes; Structure-Activity Relationship

2022
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
    Expert opinion on investigational drugs, 2022, Volume: 31, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Lung Neoplasms; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2022
Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
    European journal of medicinal chemistry, 2022, Apr-15, Volume: 234

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Oxazoles; Pentacyclic Triterpenes; Pyrazines; Structure-Activity Relationship; Zebrafish

2022
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2022, 04-11, Volume: 20, Issue:7

    Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2022
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
    Molecular cancer therapeutics, 2022, 05-04, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Oxazoles; Phosphatidylinositol 3-Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab

2022
Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers.
    European journal of medicinal chemistry, 2022, Dec-15, Volume: 244

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2

2022
Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis.
    Bioanalysis, 2022, Volume: 14, Issue:22

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Tandem Mass Spectrometry

2022
Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer.
    Cancer, 2020, 05-15, Volume: 126, Issue:10

    Topics: Breast Neoplasms; Humans; Oxazoles; Pyridines; Quinazolines; Trastuzumab

2020
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity.
    Future oncology (London, England), 2020, Volume: 16, Issue:21

    Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Immune Checkpoint Inhibitors; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2020
Highlights from the 2019 San Antonio Breast Cancer Symposium.
    Clinical advances in hematology & oncology : H&O, 2020, Volume: 18, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Oxazoles; Paclitaxel; Prognosis; Pyridines; Quinazolines; Texas; Trastuzumab

2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 03-01, Volume: 27, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration

2021
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
    Breast cancer research and treatment, 2021, Volume: 185, Issue:3

    Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2021
HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
    Critical reviews in oncogenesis, 2020, Volume: 25, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Female; Humans; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab

2020
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
    Cell death & disease, 2021, 02-15, Volume: 12, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Drug Synergism; Female; Gene Amplification; Humans; Indoles; Indolizines; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Protein Kinase Inhibitors; Pyridines; Pyridinium Compounds; Quinazolines; Quinolines; Random Allocation; Receptor, ErbB-2; Sulfonamides; Xenograft Model Antitumor Assays

2021
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.
    ESMO open, 2021, Volume: 6, Issue:2

    Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2

2021
Neratinib: an option for HER2-positive metastatic breast cancer.
    Clinical advances in hematology & oncology : H&O, 2020, Volume: 18 Suppl 15, Issue:9

    Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2020
Design and evaluation of peptide-18-targeted nanoliposomes constructed by poly(2-oxazoline)-DOPE for doxorubicin delivery.
    Journal of microencapsulation, 2021, Volume: 38, Issue:5

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Female; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liposomes; Myocytes, Smooth Muscle; Nanoparticles; Oxazoles; Particle Size; Peptides; Phosphatidylethanolamines; Scattering, Radiation

2021
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.
    Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Iridoids; Neoadjuvant Therapy; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Uncoupling Protein 2

2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 153

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult

2021
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
    Clinical breast cancer, 2022, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Staging; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Treatment Outcome; United States

2022
Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer.
    Molecular pharmaceutics, 2018, 11-05, Volume: 15, Issue:11

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Carriers; Drug Liberation; Embryo, Nonmammalian; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Nanoparticles; Oxazoles; Paclitaxel; Polymers; Treatment Outcome; Xenograft Model Antitumor Assays; Zebrafish

2018
Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments.
    Biomaterials, 2019, Volume: 192

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Drug Carriers; Drug Liberation; Female; Humans; Mice, Nude; Micelles; Ovarian Neoplasms; Oxazoles; Paclitaxel

2019
Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
    Scientific reports, 2018, 11-22, Volume: 8, Issue:1

    Topics: Ado-Trastuzumab Emtansine; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Lung Neoplasms; Marine Toxins; Maytansine; Mice; Ovarian Neoplasms; Oxazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2018
High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients.
    Analytical chemistry, 2013, Dec-17, Volume: 85, Issue:24

    Topics: Acetylation; Breast Neoplasms; Case-Control Studies; Chromatography, Liquid; Oxazoles; Polyamines; Saliva; Sulfonamides; Tandem Mass Spectrometry; Time Factors

2013
Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:7

    Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Oxazoles; Phenols; Proto-Oncogene Proteins c-bcl-2; Selective Estrogen Receptor Modulators; Signal Transduction

2014
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
    International journal of oncology, 2014, Volume: 45, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Female; Heterografts; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Real-Time Polymerase Chain Reaction; Thiazoles; X-Linked Inhibitor of Apoptosis Protein

2014
Dietary exposure in utero and during lactation to a mixture of genistein and an anti-androgen fungicide in a rat mammary carcinogenesis model.
    Reproductive toxicology (Elmsford, N.Y.), 2015, Volume: 54

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Age Factors; Androgen Antagonists; Animals; Breast Neoplasms; Carcinoma in Situ; Cell Proliferation; Diet; Disease Models, Animal; Endocrine Disruptors; Epithelial Cells; Female; Fungicides, Industrial; Genistein; Gestational Age; Mammary Glands, Animal; Maternal Exposure; Oxazoles; Pregnancy; Prenatal Education; Rats, Wistar; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tumor Burden

2015
FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Molecular cancer, 2014, Jun-14, Volume: 13

    Topics: Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chaperonins; Female; HSP90 Heat-Shock Proteins; Humans; Macrolides; MCF-7 Cells; Multiprotein Complexes; Oxazoles; Protein Binding; Receptor, ErbB-2

2014
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Jun-28, Volume: 208

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Female; Humans; Mice; Mice, Nude; Micelles; Oxazoles; Particle Size; Taxoids; Xenograft Model Antitumor Assays

2015
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:3

    Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Imidazoles; Marine Toxins; MCF-7 Cells; Okadaic Acid; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Signal Transduction; Zoledronic Acid

2016
A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.
    Biomaterials, 2016, Volume: 101

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Ovarian Neoplasms; Oxazoles; Paclitaxel

2016
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
    Toxicology in vitro : an international journal published in association with BIBRA, 2017, Volume: 38

    Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinolines; Receptor, ErbB-2; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles

2017
Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.
    Molecular endocrinology (Baltimore, Md.), 2010, Volume: 24, Issue:1

    Topics: Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Ligands; Oxazoles; Phenols; Pyrazoles; Response Elements; RNA, Small Interfering; Transcription Factors

2010
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs.
    Biomaterials, 2010, Volume: 31, Issue:18

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Complement Activation; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Inbred C57BL; Micelles; Neoplasms; Oxazoles; Paclitaxel; Polymers; Solubility

2010
Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents.
    Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; G-Quadruplexes; Humans; Ligands; Macrocyclic Compounds; Mice; Mice, Nude; Neoplasm Proteins; Oxazoles; Pyridines; RNA; Xenograft Model Antitumor Assays

2010
Total synthesis and biological evaluation of monorhizopodin and 16-epi-monorhizopodin.
    Angewandte Chemie (International ed. in English), 2011, Feb-01, Volume: 50, Issue:5

    Topics: Actins; Breast Neoplasms; Cell Line, Tumor; Humans; Macrolides; Molecular Structure; Oxazoles; Polymerization; Stereoisomerism

2011
3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.
    Journal of biomolecular screening, 2011, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Depsipeptides; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; High-Throughput Screening Assays; Humans; Imidazoles; Models, Biological; Neoplasm Metastasis; Oxazoles; Small Molecule Libraries; Spheroids, Cellular; Vimentin

2011
DNA binding and antiproliferative activity toward human carcinoma cells of copper(II) and zinc(II) complexes of a 2,5-diphenyl[1,3,4]oxadiazole derivative.
    Dalton transactions (Cambridge, England : 2003), 2012, Apr-21, Volume: 41, Issue:15

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Coordination Complexes; Copper; DNA; Female; Humans; Models, Molecular; Nucleic Acid Denaturation; Oxazoles; Zinc

2012
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
    Journal of medicinal chemistry, 2012, Mar-22, Volume: 55, Issue:6

    Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship

2012
E2F4 deficiency promotes drug-induced apoptosis.
    Cancer biology & therapy, 2004, Volume: 3, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; E2F4 Transcription Factor; Fibroblasts; Flavonoids; Humans; Lung Neoplasms; Mice; Mice, Knockout; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; RNA, Small Interfering; Roscovitine; Thiazoles; Transcription Factors; Tumor Cells, Cultured

2004
Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:10

    Topics: Animals; Breast Neoplasms; Carbon Radioisotopes; Female; Isotope Labeling; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Organ Specificity; Oxazoles; Positron-Emission Tomography; PPAR gamma; Radiopharmaceuticals; Tissue Distribution; Tyrosine

2005
G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells.
    Oncogene, 2006, Mar-23, Volume: 25, Issue:13

    Topics: Anaphase; Breast Neoplasms; Cell Death; Dose-Response Relationship, Drug; Epithelial Cells; Female; Fibroblasts; HeLa Cells; Humans; Nuclear Proteins; Oxazoles; TATA Box Binding Protein-Like Proteins; Telomere; Telomeric Repeat Binding Protein 2; Tumor Cells, Cultured

2006
Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.
    Chemistry & biology, 2007, Volume: 14, Issue:12

    Topics: Alternative Splicing; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Down-Regulation; Emetine; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Marine Toxins; Okadaic Acid; Oxazoles; Prostatic Neoplasms; Protein Phosphatase 1; Protein Phosphatase 2; Up-Regulation; Uterine Cervical Neoplasms

2007
An improved assay for radiation-induced chromatid breaks using a colcemid block and calyculin-induced PCC combination.
    Mutagenesis, 2008, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinogens; Cells, Cultured; Chromatids; Chromatin Assembly and Disassembly; Chromosome Breakage; Chromosomes, Human; Demecolcine; Humans; Marine Toxins; Mutagenicity Tests; Oxazoles; Radiation Injuries

2008
The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry.
    Research communications in chemical pathology and pharmacology, 1980, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line; Cytological Techniques; DNA, Neoplasm; gamma-Glutamyltransferase; Glycine; Humans; Isoxazoles; Oxazoles

1980
Phase II trial of acivicin in advanced metastatic breast cancer.
    Cancer treatment reports, 1983, Volume: 67, Issue:9

    Topics: Adult; Breast Neoplasms; Drug Evaluation; Female; Humans; Isoxazoles; Middle Aged; Neoplasm Metastasis; Oxazoles

1983
8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line.
    British journal of cancer, 1995, Volume: 72, Issue:5

    Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Adenocarcinoma; Adenosine Deaminase; Amino Acid Sequence; Apoptosis; Biotransformation; Breast Neoplasms; Chromatin; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA Damage; Ethers, Cyclic; Female; Humans; Marine Toxins; Microvilli; Molecular Sequence Data; Necrosis; Okadaic Acid; Organelles; Oxazoles; Phosphoprotein Phosphatases

1995
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
    Journal of cellular biochemistry, 1993, Volume: 53, Issue:3

    Topics: Alkaloids; Apoptosis; Breast Neoplasms; Carbazoles; DNA; Drug Synergism; Ethers, Cyclic; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Marine Toxins; Okadaic Acid; Oxazoles; Phosphoproteins; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1993
Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors.
    Bioorganic & medicinal chemistry, 1997, Volume: 5, Issue:1

    Topics: Breast Neoplasms; Cell Cycle; Cell Division; Drug Design; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Marine Toxins; Mass Spectrometry; Oxazoles; Phosphoprotein Phosphatases; Serine; Threonine; Tumor Cells, Cultured

1997
Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A.
    Biochemical and biophysical research communications, 1992, Dec-30, Volume: 189, Issue:3

    Topics: Antibodies, Monoclonal; Autoradiography; Blotting, Northern; Breast Neoplasms; Caseins; Cell Differentiation; Electrophoresis, Polyacrylamide Gel; Ethers, Cyclic; Female; Fluorescent Antibody Technique; Gene Expression; Genes, fos; Genes, jun; Humans; Isoenzymes; Kinetics; Marine Toxins; Microcystins; Okadaic Acid; Oligonucleotide Probes; Oxazoles; Peptides, Cyclic; Phosphates; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorus Radioisotopes; Phosphorylation; Pyrans; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

1992
Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
    Cancer research, 1990, Sep-01, Volume: 50, Issue:17

    Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cats; Central Nervous System; Electrolytes; Female; Glucose; Humans; Infusions, Intravenous; Isoxazoles; Leukemia L1210; Male; Mice; Mice, Inbred Strains; Mice, Nude; Oxazoles; Parenteral Nutrition Solutions; Reference Values; Solutions; Transplantation, Heterologous

1990
Distribution of 14 C-isoxazole in adrenals, ovaries, and breast carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1973, Volume: 14, Issue:6

    Topics: Adenocarcinoma, Scirrhous; Adipose Tissue; Adrenal Glands; Adult; Aged; Animals; Benz(a)Anthracenes; Breast Neoplasms; Carbon Isotopes; Carcinoma, Intraductal, Noninfiltrating; Fallopian Tubes; Female; Humans; Hydroxysteroid Dehydrogenases; Isomerases; Kidney; Liver; Mammary Neoplasms, Experimental; Middle Aged; Muscles; Ovary; Oxazoles; Rats; Skin

1973